164 related articles for article (PubMed ID: 38077396)
1. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract][Full Text] [Related]
2. EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules.
Liu Y; Lui KS; Ye Z; Fung TY; Chen L; Sit PY; Leung CY; Mak NK; Wong KL; Lung HL; Tanaka Y; Cheung AKL
Theranostics; 2023; 13(2):458-471. PubMed ID: 36632221
[TBL] [Abstract][Full Text] [Related]
3. Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.
Umeyama Y; Taniguchi H; Gyotoku H; Senju H; Tomono H; Takemoto S; Yamaguchi H; Tagod MSO; Iwasaki M; Tanaka Y; Mukae H
Front Immunol; 2023; 14():1058838. PubMed ID: 37006249
[TBL] [Abstract][Full Text] [Related]
4. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.
Wang H; Chen H; Liu S; Zhang J; Lu H; Somasundaram R; Choi R; Zhang G; Ou L; Scholler J; Tian S; Dong L; Yeye G; Huang L; Connelly T; Li L; Huang A; Mitchell TC; Fan Y; June CH; Mills GB; Guo W; Herlyn M; Xu X
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34937742
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Butyrophilin-Mediated Activation of γδ T Cells from Human Spleen.
Wang C; Lai AY; Baiu DC; Smith KA; Odorico JS; Wilson K; Schreiber T; de Silva S; Gumperz JE
J Immunol; 2024 Jan; 212(2):284-294. PubMed ID: 37991420
[TBL] [Abstract][Full Text] [Related]
6. Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma.
van Gulijk M; Belderbos B; Dumoulin D; Cornelissen R; Bezemer K; Klaase L; Dammeijer F; Aerts J
Int J Cancer; 2023 Apr; 152(7):1438-1443. PubMed ID: 36104949
[TBL] [Abstract][Full Text] [Related]
7. Malignant Mesothelioma Effusions Are Infiltrated by CD3
Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
[TBL] [Abstract][Full Text] [Related]
8. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
Front Immunol; 2021; 12():654080. PubMed ID: 34040604
[TBL] [Abstract][Full Text] [Related]
9. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
Front Immunol; 2018; 9():2034. PubMed ID: 30245692
[No Abstract] [Full Text] [Related]
10. γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.
Jiang H; Yang Z; Song Z; Green M; Song H; Shao Q
Int Immunopharmacol; 2019 May; 70():167-173. PubMed ID: 30802679
[TBL] [Abstract][Full Text] [Related]
11. Preclinical platforms to study therapeutic efficacy of human γδ T cells.
Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X
Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
[TBL] [Abstract][Full Text] [Related]
13. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells.
Cano CE; Pasero C; De Gassart A; Kerneur C; Gabriac M; Fullana M; Granarolo E; Hoet R; Scotet E; Rafia C; Herrmann T; Imbert C; Gorvel L; Vey N; Briantais A; le Floch AC; Olive D
Cell Rep; 2021 Jul; 36(2):109359. PubMed ID: 34260935
[TBL] [Abstract][Full Text] [Related]
14. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K; Zygoura P; Norkin M; Tissot S; Shakarishvili N; Popat S; Curioni-Fontecedro A; O'Brien M; Pope A; Shah R; Fisher P; Spicer J; Roy A; Gilligan D; Rusakiewicz S; Fortis E; Marti N; Kammler R; Finn SP; Coukos G; Dafni U; Peters S; Stahel RA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880184
[TBL] [Abstract][Full Text] [Related]
15. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Transporters.
Rhodes DA; Chen HC; Williamson JC; Hill A; Yuan J; Smith S; Rhodes H; Trowsdale J; Lehner PJ; Herrmann T; Eberl M
Front Immunol; 2018; 9():662. PubMed ID: 29670629
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
19. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
Sule Kutlar Dursun F; Alabalik U
Pol J Pathol; 2022; 73(2):111-119. PubMed ID: 36172747
[TBL] [Abstract][Full Text] [Related]
20. Exhausted intratumoral Vδ2
Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
